CCI fines Goldman Sachs for undisclosed investment in Biocon, highlighting need for compliance with competition laws in ...
Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...
According to reports, HSBC said that Biocon is well-placed for an operational turnaround, driven by key biosimilar launches ...
Biocon's shares surged over 7% on January 14, 2025, after HSBC upgraded its rating to 'Buy' with a target price of ₹430, ...
Zomato slips on Jefferies' downgrade, Biocon rallies on USFDA approval and Jefferies upgrade, ONGC gains as CLSA names it a ...
Biocon Ltd shares rose 4.7% after HSBC upgraded its rating to "buy" and raised the target price to Rs 430. The upgrade ...
HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...
With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...
Biocon has experienced a significant earnings decline over the past two years, led by a lack of potential approvals for the U ...
The market is expected to consolidate as long as it trades below all key moving averages. Below are some trading ideas for ...
The Competition Commission of India fined Goldman Sachs AIMPL Rs 40 lakh for not notifying it about a deal that included ...
Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated.